2,6-bis(propan-2-yl)phenol

• ChemBase ID: 697
• Molecular Formular: C12H18O
• Molecular Mass: 178.27072
• Monoisotopic Mass: 178.1357652
• SMILES: Oc1c(C(C)C)cccc1C(C)C
• Canonical SMILES: CC(c1cccc(c1O)C(C)C)C
• InChI: InChI=1S/C12H18O/c1-8(2)10-6-5-7-11(9(3)4)12(10)13/h5-9,13H,1-4H3
• InChIKey: OLBCVFGFOZPWHH-UHFFFAOYSA-N

NAMES AND DATABASE IDS

Names

• IUPAC name: 2,6-bis(propan-2-yl)phenol
• IUPAC Traditional name: propofol
• Brand Name: Diprivan; Disoprivan; Disoprofol; Rapinovet
• Synonyms: 2,6-Bis(isopropyl)phenol; Propofol; 2,6-Diisopropylphenol; 2,6-DIISOPROPYLPHENOL; Diprivan; Propofol (Diprivan); 2,6-Diisopropylphenol; Diisopropylphenol; Propofol; 2,6-Bis(1-methylethyl)phenol; Ampofol; Anepol; Aquafol; Diprifusor; Diprivan 10; Diprofol; Disoprivan; Disoprofol; Fresofol; ICI 35868; Ivofol; NSC 5105; PD 18215; Plofed; Pofol; Pronest; PropVet; Propofol-lipuro; Propovan; Rapinovet; Recofol; Vetofol; 2,6-二异丙基苯酚; 普鲁泊福; 丙泊酚; 2,6-二异丙基苯酚

Database IDs

• CAS Number: 2078-54-8
• EC Number: 218-206-6
• MDL Number: MFCD00008885
• Beilstein Number: 1866484
• Merck Index: 147834
• PubChem SID: 46504991; 24278001; 160964160; 24902022
• PubChem CID: 4943

CALCULATED PROPERTIES

JChem

• Acid pKa: 10.983676
• H Acceptors: 1
• H Donor: 1
• LogD (pH = 5.5): 4.1596975
• LogD (pH = 7.4): 4.159586
• Log P: 4.159699
• Molar Refractivity: 56.4205 cm^3
• Polarizability: 21.854183 Å^3
• Polar Surface Area: 20.23 Å^2
• Rotatable Bonds: 2
• Lipinski's Rule of Five: true

ALOGPS 2.1

• Log P: 3.81
• LOG S: -3.05
• Solubility (Water): 1.58e-01 g/l

PROPERTIES

Physical Property

• Solubility: 124 mg/L; DMSO; Methanol
• Apperance: Pale Yellow Oil
• Melting Point: 17-18°C; 18 °C(lit.); 18°C
• Boiling Point: 136°C; 254-256°C; 256 °C/764 mmHg(lit.); 256°C
• Flash Point: 113 °C; 113°C(235°F); 235.4 °F
• Density: 0.962; 0.962 g/ml; 0.962 g/mL at 25 °C(lit.)
• Refractive Index: 1.5140; n20/D 1.514(lit.)
• Vapor Pressure: 5.6 mmHg ( 100 °C)
• Hydrophobicity(logP): 4

Safety Information

• Storage Condition: -20°C; Refrigerator, Under Inert Atmosphere; Room Temperature (15-30°C), Desiccate, Protect from light
• RTECS: SL0810000
• European Hazard Symbols: Corrosive (C); X; Harmful (Xn)
• UN Number: 3145
• German water hazard class: 3
• Hazard Class: 8
• Packing Group: II
• Australian Hazchem: 2X
• Risk Statements: 22-36/37/38; 22-36/38; R:22; R:22-34
• Safety Statements: 26-36/37; 26-36/37/39; S:26-27/28-36/37/39-46-64; S:36/37/39
• EU Classification: C3
• EU Hazard Identification Number: 8B
• Emergency Response Guidebook(ERG) Number: 153
• TSCA Listed: 是
• GHS Pictograms: GHS06; GHS07
• GHS Signal Word: Warning
• GHS Hazard statements: H301-H315-H319; H302-H315-H319-H335
• GHS Precautionary statements: P261-P305 + P351 + P338; P280-P301+P310-P305+P351+P338-P302+P352-P405-P501A
• Personal Protective Equipment: Eyeshields, Faceshields, full-face respirator (US), Gloves, multi-purpose combination respirator cartridge (US), type ABEK (EN14387) respirator filter

Pharmacology Properties

• Target: GABA transporter
• Gene Information: human ... CYP1A2(1544), GABRA1(2554)rat ... Gabra2(29706)

Product Information

• Purity: ≥97%; 97%
• Salt Data: Free Base
• Linear Formula: [(CH3)2CH]2C6H3OH

DETAILS

MP Biomedicals - 02193707

A short acting general anesthetic which exhibits direct activation of the GABA_A receptor and inhibition of glutamate receptor-mediated synaptic transmission.

DrugBank - DB00818

• Drug Groups: approved; investigational
• Description: Propofol is an intravenous anaesthetic agent used for induction and maintenance of general anaesthesia. IV administration of propfol is used to induce unconsciousness after which anaesthesia may be maintained using a combination of medications. Recovery from propofol-induced anaesthesia is generally rapid and associated with less frequent side effects (e.g. drowsiness, nausea, vomiting) than with thiopental, methohexital, and etomidate. Propofol may be used prior to diagnostic procedures requiring anaesthesia, in the management of refractory status epilepticus, and for induction and/or maintenance of anaesthesia prior to and during surgeries.
• Indication: Used for induction and/or maintenance of anaesthesia and for management of refractory status epilepticus.
• Pharmacology: Propofol is a sedative-hypnotic agent for use in the induction and maintenance of anesthesia or sedation. Intravenous injection of a therapeutic dose of propofol produces hypnosis rapidly with minimal excitation, usually within 40 seconds from the start of an injection (the time for one arm-brain circulation).
• Toxicity: Overdosage may increase pharmacologic and adverse effects or cause death. ;

  IV LD₅₀=53 mg/kg (mice), 42 mg/kg (rats). Oral LD₅₀ (as a solution in soybean oil)=1230 mg/kg (mice), 600 mg/kg (rats)

• Affected Organisms: Humans and other mammals
• Biotransformation: Hepatically metabolized mainly by glucuronidation at the C1-hydroxyl. Hydroxylation of the benzene ring to 4-hydroxypropofol may also occur via CYP2B6 and 2C9 with subsequent conjugation to sulfuric and/or glucuronic acid. Hydroxypropofol has approximately 1/3 of hypnotic activity of propofol.
• Absorption: Rapid - time to onset of unconsciousness is 15-30 seconds, due to rapid distribution from plasma to the CNS. Distribution is so rapid that peak plasma concentrations cannot be readily measured. Duration of action is 5-10 minutes.
• Half Life: Initial distribution phase t_1/2α=1.8-9.5 minutes. Second redistirubtion phase t_1/2β=21-70 minutes. Terminal elimination phase t_1/2γ=1.5-31 hours.
• Protein Binding: 95 to 99%, primarily to serum albumin and hemoglobin
• Elimination: It is chiefly eliminated by hepatic conjugation to inactive metabolites which are excreted by the kidney.
• Distribution: * 60 L/kg [healthy adults]
• Clearance: * 23 - 50 mL/kg/min; * 1.6 - 3.4 L/min [70 Kg adults]
• References: Vasile B, Rasulo F, Candiani A, Latronico N: The pathophysiology of propofol infusion syndrome: a simple name for a complex syndrome. Intensive Care Med. 2003 Sep;29(9):1417-25. Epub 2003 Aug 6. [Pubmed] ; Ke JJ, Zhan J, Feng XB, Wu Y, Rao Y, Wang YL: A comparison of the effect of total intravenous anaesthesia with propofol and remifentanil and inhalational anaesthesia with isoflurane on the release of pro- and anti-inflammatory cytokines in patients undergoing open cholecystectomy. Anaesth Intensive Care. 2008 Jan;36(1):74-8. [Pubmed] ; Hong JY, Kang YS, Kil HK: Anaesthesia for day case excisional breast biopsy: propofol-remifentanil compared with sevoflurane-nitrous oxide. Eur J Anaesthesiol. 2008 Feb 26;:1-8. [Pubmed]
• External Links: Wikipedia; RxList; Drugs.com

Selleck Chemicals - S2023

Research Area: Cancer
Biological Activity:
Propofol (Diprivan) is a short-acting, intravenously administered hypnotic agent. Its uses include the induction and maintenance of general anesthesia, sedation for mechanically ventilated adults, and procedural sedation. Propofol (Diprivan) is also commonly used in veterinary medicine. Both through potentiation of GABAA receptor activity, thereby slowing the channel-closing time, and also acting as a sodium channel blocker. [1]References on Propofol (Diprivan)[1] http://en.wikipedia.org/wiki/Propofol, ,

Sigma Aldrich - W505102

Packaging
1 kg in glass bottle
25, 100 g in glass bottle

Sigma Aldrich - D126608

Packaging
5, 100 g in glass bottle

Toronto Research Chemicals - P829750

Propofol is an anesthetic used in veterinary medicine.

REFERENCES

• Orser, et al., Br. J. Pharmacol. , 116 : 1761 (1995).
• Vasile B, Rasulo F, Candiani A, Latronico N: The pathophysiology of propofol infusion syndrome: a simple name for a complex syndrome. Intensive Care Med. 2003 Sep;29(9):1417-25. Epub 2003 Aug 6. Pubmed
• Ke JJ, Zhan J, Feng XB, Wu Y, Rao Y, Wang YL: A comparison of the effect of total intravenous anaesthesia with propofol and remifentanil and inhalational anaesthesia with isoflurane on the release of pro- and anti-inflammatory cytokines in patients undergoing open cholecystectomy. Anaesth Intensive Care. 2008 Jan;36(1):74-8. Pubmed
• Hong JY, Kang YS, Kil HK: Anaesthesia for day case excisional breast biopsy: propofol-remifentanil compared with sevoflurane-nitrous oxide. Eur J Anaesthesiol. 2008 Feb 26;:1-8. Pubmed
• http://en.wikipedia.org/wiki/Propofol
• Glen, J.B., and Hunter, S.C.: Brit. J. Anaesth., 56, 617 (1984)
• Kohnen, S.L., et al.: Nitric Oxide, 8, 170 (2003)